News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CIGNA Corporation Demands Counseling for Breast Test in Myriad Genetics, Inc. (MYGN) Threat



8/19/2013 7:52:32 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Cigna Corp. (CI) will become the first U.S. health insurer to require genetic counseling nationwide before it pays for tests for hereditary breast and ovarian cancer, a move that may threaten sales for Myriad Genetics Inc. (MYGN) The policy affects tests for the BRCA1 and BRCA2 genes, the most common cause of hereditary breast cancer, as well as genes for hereditary colon cancer and a heart abnormality called long QT syndrome, David Finley, a national medical officer for the Bloomfield, Connecticut-based insurer, said in an Aug. 16 interview. It takes effect Sept. 16.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at Street Insider
Read at Seeking Alpha


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES